On October 27, 2020 Humanigen, Inc., (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab, reported that the Company’s management will present or participate in panel discussions at the following upcoming virtual investor conferences (Press release, Humanigen, OCT 27, 2020, View Source [SID1234569146]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ROTH Capital Healthcare Event – COVID-19 Therapeutics in Development (October 28, 2020)
Date: Wednesday, October 28
Panel series: Immune Modulators to Ameliorate COVID Sequelae 2
Panel time: 9:00 AM ET
Registration link: View Source

Bryan, Garnier & Co European Healthcare Conference (November 16-17, 2020)
Date: Monday, November 16
For more information: View Source

Stifel Virtual Healthcare Conference (November 16-18, 2020)
Date: Tuesday, November 17
Presentation time: 1:20 PM ET
Live webcast link: View Source

Jefferies London Healthcare Conference (November 17-19, 2020)
Date: Thursday, November 19
Presentation time: 6:45 PM GMT (2:45 PM ET)
Live webcast link: View Source

The conferences are being held in a virtual format. A live webcast of the presentation may be accessed on the Events section of the Humanigen website View Source Archived replay will be available on the Company website for 30 days following the event.